Incretin Atlas › Trials › PEX168 monotherapy phase 3a
PEX168 monotherapy phase 3a
PEG-loxenatide · t2d
Design
- Molecule(s)
- PEG-loxenatide
- Population
- t2d
- Phase
- 3
- Participants
- 361
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 μg | t2d china | 24 | 361 | — | — | −1.0 vs −0.2 | 1.6 vs 0.8 | — | 5.6 vs 0.0 | 2.4 vs 0.0 | — | — | press release |
| 200 μg | t2d china | 24 | 361 | — | — | −1.3 vs −0.2 | 2.5 vs 0.8 | — | 10.0 vs 0.0 | 8.3 vs 0.0 | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (8)
- 100 μg · hba1c · publication
The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
- 100 μg · nausea · publication
nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 100 μg · vomiting · publication
vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 100 μg · ae_dc · publication
(PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
- 200 μg · hba1c · publication
The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
- 200 μg · nausea · publication
nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 200 μg · vomiting · publication
vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 200 μg · ae_dc · publication
(PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: PEX168 monotherapy phase 3a. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-monotherapy-phase-3a/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.